Related references
Note: Only part of the references are listed.Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure
Deepak L. Bhatt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Effect of empagliflozin on ectopic fat stores and myocardial energetics in type 2 diabetes: the EMPACEF study
B. Gaborit et al.
CARDIOVASCULAR DIABETOLOGY (2021)
A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation, cardiac function, and cardiac metabolism in patients with early-stage type 2 diabetes: the ASSET study
Shigenori Hiruma et al.
CARDIOVASCULAR DIABETOLOGY (2021)
Unexpected Pleiotropic Effects of SGLT2 Inhibitors: Pearls and Pitfalls of This Novel Antidiabetic Class
Hideaki Kaneto et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Multi-Organ Protective Effects of Sodium Glucose Cotransporter 2 Inhibitors
Hidekatsu Yanai et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Design and rationale of the EMPA-VISION trial: investigating the metabolic effects of empagliflozin in patients with heart failure
Moritz J. Hundertmark et al.
ESC HEART FAILURE (2021)
Effect of tofogliflozin on cardiac and vascular endothelial function in patients with type 2 diabetes and heart diseases: A pilot study
Mayu Tochiya et al.
JOURNAL OF DIABETES INVESTIGATION (2020)
Effect of dapagliflozin on arterial stiffness in patients with type 2 diabetes mellitus
Juan Carlos Hidalgo Santiago et al.
MEDICINA CLINICA (2020)
Comorbidities in chronic heart failure: An update from Italian Society of Cardiology (SIC) Working Group on Heart Failure
Michele Correale et al.
EUROPEAN JOURNAL OF INTERNAL MEDICINE (2020)
Role of endothelial dysfunction in heart failure
Cinzia Zuchi et al.
HEART FAILURE REVIEWS (2020)
Effects of antidiabetic drugs on left ventricular function/dysfunction: a systematic review and network meta-analysis
Da-Peng Zhang et al.
CARDIOVASCULAR DIABETOLOGY (2020)
European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure
Petar M. Seferovic et al.
EUROPEAN JOURNAL OF HEART FAILURE (2020)
Empagliflozin ameliorates endothelial dysfunction and suppresses atherogenesis in diabetic apolipoprotein E-deficient mice
Byambasuren Ganbaatar et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2020)
Metabolic and cardiovascular benefits of GLP-1 agonists, besides the hypoglycemic effect (Review)
Roua Anamaria Iorga et al.
EXPERIMENTAL AND THERAPEUTIC MEDICINE (2020)
Effects of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12-Month Treatment
Ignatios Ikonomidis et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2020)
Sodium-glucose co-transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology
Petar M. Seferovic et al.
EUROPEAN JOURNAL OF HEART FAILURE (2020)
Rationale and design of an investigator-initiated, multicenter, prospective open-label, randomized trial to evaluate the effect of ipragliflozin on endothelial dysfunction in type 2 diabetes and chronic kidney disease: the PROCEED trial
Atsushi Tanaka et al.
CARDIOVASCULAR DIABETOLOGY (2020)
Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease A Review
Michael C. Honigberg et al.
JAMA CARDIOLOGY (2020)
Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure The Need for Further Evidence Generation and Practice Guidelines Optimization
Muhammad Shahzeb Khan et al.
CIRCULATION (2020)
Heart Failure Association of the European Society of Cardiology update on sodium-glucose co-transporter 2 inhibitors in heart failure (an update on the sodium-glucose co-transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology)
Petar M. Seferovic et al.
EUROPEAN JOURNAL OF HEART FAILURE (2020)
Secondary analyses to assess the profound effects of empagliflozin on endothelial function in patients with type 2 diabetes and established cardiovascular diseases: The placebo-controlled double-blind randomized effect of empagliflozin on endothelial function in cardiovascular high risk diabetes mellitus: Multi-center placebo-controlled double-blind randomized trial
Atsushi Tanaka et al.
JOURNAL OF DIABETES INVESTIGATION (2020)
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
Milton Packer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes
Christopher P. Cannon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Non-insulin antihyperglycaemic drugs and heart failure: an overview of current evidence from randomized controlled trials
Gianluigi Savarese et al.
ESC HEART FAILURE (2020)
Switch to direct anticoagulants and improved endothelial function in patients with chronic heart failure and atrial fibrillation
Michele Correale et al.
THROMBOSIS RESEARCH (2020)
Rationale and design of the expanded combination of evolocumab plus empagliflozin in diabetes: EXCEED-BHS3 trial
Ikaro Breder et al.
THERAPEUTIC ADVANCES IN CHRONIC DISEASE (2020)
Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors A State-of-the-Art Review
Gary D. Lopaschuk et al.
JACC-BASIC TO TRANSLATIONAL SCIENCE (2020)
How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial
Agnes Bosch et al.
CARDIOVASCULAR DIABETOLOGY (2019)
Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics
Carlos G. Santos-Gallego et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Empagliflozin restores the integrity of the endothelial glycocalyx in vitro
Scott Cooper et al.
MOLECULAR AND CELLULAR BIOCHEMISTRY (2019)
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Mansoor Husain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Assessment of dapagliflozin effect on diabetic endothelial dysfunction of brachial artery (ADDENDA-BHS2 trial): rationale, design, and baseline characteristics of a randomized controlled trial
Riobaldo M. R. Cintra et al.
DIABETOLOGY & METABOLIC SYNDROME (2019)
Effect of Once-Weekly Exenatide in Patients With Type 2 Diabetes Mellitus With and Without Heart Failure and Heart Failure-Related Outcomes Insights From the EXSCEL Trial
Marat Fudim et al.
CIRCULATION (2019)
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
J. J. V. McMurray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Soren L. Kristensen et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
S. D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Cardiac Microvascular Endothelial Enhancement of Cardiomyocyte Function Is Impaired by Inflammation and Restored by Empagliflozin
Rio P. Juni et al.
JACC-BASIC TO TRANSLATIONAL SCIENCE (2019)
Endothelial dysfunction and heart failure: A review of the existing bibliography with emphasis on flow mediated dilation
Sofia Giannitsi et al.
JRSM CARDIOVASCULAR DISEASE (2019)
Effects of Glucagon-Like Peptide-1 on Oxidative Stress and Nrf2 Signaling
Yoon Sin Oh et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Empagliflozin influences blood viscosity and wall shear stress in subjects with type 2 diabetes mellitus compared with incretin-based therapy
Concetta Irace et al.
CARDIOVASCULAR DIABETOLOGY (2018)
SGLT2 inhibition via dapagliflozin improves generalized vascular dysfunction and alters the gut microbiota in type 2 diabetic mice
Dustin M. Lee et al.
CARDIOVASCULAR DIABETOLOGY (2018)
SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review
Subodh Verma et al.
DIABETOLOGIA (2018)
Redefining biomarkers in heart failure
Michele Correale et al.
HEART FAILURE REVIEWS (2018)
The anti-diabetic drug dapagliflozin induces vasodilation via activation of PKG and Kv channels
Hongliang Li et al.
LIFE SCIENCES (2018)
Canagliflozin inhibits interleukin-1 beta-stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and -independent mechanisms
Sarah J. Mancini et al.
SCIENTIFIC REPORTS (2018)
Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis
Muhammad Shariq Usman et al.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2018)
Empagliflozin on top of metformin treatment improves arterial function in patients with type 1 diabetes mellitus
Mojca Lunder et al.
CARDIOVASCULAR DIABETOLOGY (2018)
Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure
Fumitaka Soga et al.
CARDIOVASCULAR DIABETOLOGY (2018)
GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data
Andrei C. Sposito et al.
CARDIOVASCULAR DIABETOLOGY (2018)
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
Adrian F. Hernandez et al.
LANCET (2018)
Effects of Newer Antidiabetic Drugs on Endothelial Function and Arterial Stiffness: A Systematic Review and Meta-Analysis
Konstantinos Batzias et al.
JOURNAL OF DIABETES RESEARCH (2018)
Liraglutide and weight loss among patients with advanced heart failure and a reduced ejection fraction: insights from the FIGHT trial
Abhinav Sharma et al.
ESC HEART FAILURE (2018)
Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial
Anders Jorsal et al.
EUROPEAN JOURNAL OF HEART FAILURE (2017)
The diabetic heart utilizes ketone bodies as an energy source
Yuji Mizuno et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2017)
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
Rury R. Holman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study
Anna Solini et al.
CARDIOVASCULAR DIABETOLOGY (2017)
Effects of the Selective Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin on Vascular Function and Central Hemodynamics in Patients With Type 2 Diabetes Mellitus
Kristina Striepe et al.
CIRCULATION (2017)
Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors
Michael A. Nauck et al.
CIRCULATION (2017)
Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study
Fumika Shigiyama et al.
CARDIOVASCULAR DIABETOLOGY (2017)
Current Pharmacological Therapies in Heart Failure Patients
Maria Lorenza Muiesan et al.
HIGH BLOOD PRESSURE & CARDIOVASCULAR PREVENTION (2017)
Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial
Atsushi Tanaka et al.
CARDIOVASCULAR DIABETOLOGY (2017)
A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation
Christian Ott et al.
CARDIOVASCULAR DIABETOLOGY (2017)
Nrf2 signaling and redox homeostasis in the aging heart: A potential target to prevent cardiovascular diseases?
Alejandro Silva-Palacios et al.
AGEING RESEARCH REVIEWS (2016)
Exenatide exerts direct protective effects on endothelial cells through the AMPK/Akt/eNOS pathway in a GLP-1 receptor-dependent manner
Rui Wei et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2016)
Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control
Young-Sun Lee et al.
MEDIATORS OF INFLAMMATION (2016)
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Effects of the Novel Long-Acting GLP-1 Agonist, Albiglutide, on Cardiac Function, Cardiac Metabolism, and Exercise Capacity in Patients With Chronic Heart Failure and Reduced Ejection Fraction
John J. Lepore et al.
JACC-HEART FAILURE (2016)
Sodium-glucose cotransporter 2 inhibition: cardioprotection by treating diabetes-a translational viewpoint explaining its potential salutary effects
Anne E. de Leeuw et al.
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY (2016)
Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes
R. Chilton et al.
DIABETES OBESITY & METABOLISM (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Marc A. Pfeffer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study
Manfredi Rizzo et al.
CARDIOVASCULAR DIABETOLOGY (2014)
Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells
Young-Sun Lee et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2014)
Glucagon-like Peptide-1 Receptor Agonist Liraglutide Inhibits Endothelin-1 in Endothelial Cell by Repressing Nuclear Factor-Kappa B Activation
Yao Dai et al.
CARDIOVASCULAR DRUGS AND THERAPY (2013)
Glucagon-Like Peptide-1 Counteracts Oxidative Stress-Dependent Apoptosis of Human Cardiac Progenitor Cells by Inhibiting the Activation of the c-Jun N-terminal Protein Kinase Signaling Pathway
L. Laviola et al.
ENDOCRINOLOGY (2012)
Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials
Tina Vilsboll et al.
BMJ-BRITISH MEDICAL JOURNAL (2012)
Nrf2 Protects Against Maladaptive Cardiac Responses to Hemodynamic Stress
Jinqing Li et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2009)
Share Paper
